For the promising effect on β cell protection, DPP4-Is have been studied in humans for the treatment of Type 1 diabetes (T1DM) and LADA and data showed better glycemic control in patients treated with DPP4-Is in addition to a traditional insulin regimen in comparison to insulin alone [89]. The gene discussed is DPP4; the disease is type 1 diabetes mellitus.